Clinical trial
Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects
NCT00434577 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00434577 |
|---|---|
| Title | Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects |
| Official title | A Phase II, Single-blind, Randomized, Controlled, Multicentre Vaccination Study to Evaluate the Safety and Immune Response of the GSK Biologicals Zoster Vaccine, gE/AS01B, and to Compare 3 Doses of gE With AS01B Adjuvant in Healthy Elderly Subjects, Aged 60 to 69 Years and 70 Years and Above. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Herpes Zoster |
| Intervention type | Biological |
| Interventions | Herpes Zoster vaccine GSK1437173A Low Dose, Herpes Zoster vaccine GSK1437173A Medium Dose, Herpes Zoster vaccine GSK1437173A High Dose, Herpes Zoster vaccine GSK1437173A Modified, Placebo |
| Enrollment | 715 |
| Start date | Feb 14, 2007 |
| Primary completion | Oct 4, 2007 |
| Completion | Jul 14, 2010 |
| First posted | Feb 13, 2007 |
| Last update posted | Mar 15, 2019 |
| Countries | Czechia, Germany, Netherlands, Sweden |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: